C4 Therapeutics, Inc.

CCCC Healthcare Biotechnology

C4 Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $35.9 million, up 1.02% from fiscal 2024. In the quarter to June 2026, revenue grew 2.75%, EPS grew 51.4% and free cash flow grew 86.8%, each against the same quarter a year earlier.

2.77 0.01 −0.36%
Market cap
$342.0M
P/E
0.0×
Fwd P/E
−4.1×
Dividend yield
—
F-score
4/9
Altman Z
−2.16
Beneish M
−2.61
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
5 3 4 2

+8 more TTM periods

ROE
(48.14%) (48.35%) (44.44%) (59.98%)
ROA
(30.92%) (32.02%) (29.63%) (37.12%)
ROIC
0.00% 0.00% (894.58%) 0.00%
Return on Tangible Assets
(46.35%) (46.63%) (45.68%) (67.64%)
Average Days of Receivables
13.90 30.19 24.38 79.31
Free Cash Flow per Share
(0.65) (0.76) (1.20) (1.31)
Free Cash Flow
(85.39) (96.02) (99.30) (95.06)
Capital Expenditures
(0.52) (0.67) (0.60) (0.58)
Other line items
Cash ROIC
(17.05%) (20.43%) (19.66%) (27.45%)
Accounts Receivable Turnover
20.07 6.39 13.06 3.57
Accounts Payable Turnover
0.00 0.00 0.00 0.00
Average Days of Payables
0.00 0.00 0.00 0.00
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
285.53% 291.94% 289.98% 371.23%
Selling, General and Administrative Expense of Revenue
102.81% 103.83% 100.69% 124.19%
Share Based Compensation of Revenue
40.83% 46.65% 53.13% 77.48%
Interest Coverage
8.63 8.75 6.70 —
Operating CF/Net income
0.84 0.92 0.94 0.79
Depreciation/Fixed assets
(0.26) (0.25) (0.17) (0.18)
Capex/Depreciation
0.49 0.59 0.77 0.61
Revenue per Share
0.27 0.28 0.43 0.41
Operating CF per Share
(0.65) (0.76) (1.19) (1.30)
Capex per Share
0.00 (0.01) (0.01) (0.01)
Capex to Sales
0.01 0.02 0.02 0.02

Fold the line items

Columns are period end dates